<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (M 4) with t(6; 11) showed recovery to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)-like bone marrow after one course of <z:chebi fb="0" ids="15918">DCMP</z:chebi> regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Dysplastic changes of three cell-lineages were observed and micromegakaryocytes were markedly increased in number </plain></SENT>
<SENT sid="2" pm="."><plain>Recovering hematopoiesis was incomplete </plain></SENT>
<SENT sid="3" pm="."><plain>During <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-like phase, t(6; 11) disappeared, reverting to <z:mpath ids='MPATH_458'>normal</z:mpath> karyotypes </plain></SENT>
<SENT sid="4" pm="."><plain>Low dose ara-C regimen did not show any effect </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> soon relapsed with reappearance of t(6; 11) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-like <z:mp ids='MP_0002123'>abnormal hematopoiesis</z:mp> has recently been reported to occur after remission induction therapy or at the time of relapse </plain></SENT>
<SENT sid="7" pm="."><plain>G-6PD isozyme study revealed in a remission case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> that hematopoiesis still consisted of abnormal clone in spite of karyotypic normalization </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:mp ids='MP_0002123'>abnormal hematopoiesis</z:mp> observed in our case can be referred to such a clonal disorder predominating after disappearance of blastic component of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>It seems important to reveal what proportion of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> shows such an <z:mp ids='MP_0002123'>abnormal hematopoiesis</z:mp> and to establish suitable therapeutic approach </plain></SENT>
</text></document>